Study #2021-0329
A Phase II Clinical Trial of “Off-the-shelf” NK cell administration in combination with allogeneic SCT to decrease disease relapse in patients with high-risk Myeloid malignancies undergoing Matched related, Matched unrelated, One antigen mismatched unrela
MD Anderson Study Status
Not Accepting
Treatment Agent
Cyclophosphamide, Mesna, Filgrastim, Melphalan, Fludarabine phosphate, Tacrolimus, Mycophenolate mofetil, Total Body Irradiation One Dose
Description
The goal of this clinical research study is to learn about the safety and effectiveness of giving KDS-1001 in combination with a standard stem cell transplant to patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myeloid leukemia (CML). KDS-1001 is a study product created using certain immune cells called natural killer (NK) cells collected from a third-party donor.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloid Malignancies, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Study phase:
Physician name:
Jeremy Ramdial
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-855-625-0962
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.